99mTc Nanocoll: A radiopharmaceutical for sentinel node localisation in breast cancer-In vitro and in vivo results

Applied Radiation and Isotopes

Volumn 67, Issue 9, 2009, Pages 1550-1558

  Gommans, G M M ^a,b   Gommans, E ^d   van der Zant, F M ^b   Teule, G J J ^c   van der Schors, T G ^a   de Waard, J W D ^a  

^a West Fries Hospital Hoorn   (Netherlands)

^b Northwest Clinics   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Colloid albumin; Labelling efficiency; Radiochemical purity; Radiopharmacy; Sentinel node

Indexed keywords

BREAST CANCER; COUNT RATES; EX-VIVO; IN-VACUUM; IN-VITRO; LABELLING EFFICIENCY; LOCALISATION; RADIOCHEMICAL PURITY; RADIOPHARMACY; SENTINEL NODE;

TECHNETIUM;

COLLOID CHEMISTRY;

ALBUMIN; NANOCOLL TC 99M; NITROGEN; ALBUMINOID; DIAGNOSTIC AGENT; MACROSALB TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM TC 99M NANOCOLLOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PURITY; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOCHEMISTRY; SENTINEL LYMPH NODE; BREAST TUMOR; CHEMISTRY; FEMALE; LYMPH NODE; MIDDLE AGED; SCINTISCANNING; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NITROGEN; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM TC 99M AGGREGATED ALBUMIN; YOUNG ADULT;

EID: 67349260703     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.02.091     Document Type: Article

References (28)

1. Abraham J., Wilhelm G., Mijnhout S., and Franssen E.J.F. Radiopharmaceuticals in sentinel lymph node detection, an overview. Eur. J. Nucl. Med. 26 Suppl (1999) S36-S42
2. 99Tc ratios on count rates in sentinel node procedures: a randomised study. Eur. J. Nucl. Med. 31 (2004) 306
3. Bergquist L., and Strand S.E. Autocorrelation spectroscopy for particle sizing and purity tests of radiolabelled colloidals. Eur. J. Nucl. Med. 15 (1989) 641-645
4. Billinghurst M.W., and Jette D. Colloidal particle-size determination by gel filtration. J. Nucl. Med. 20 (1979) 133-137
5. Borgstein P.J., Pijpers R., Comans E.F., van Diest P.J., Boom R.P., and Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J. Am. Coll. Surg. 186 (1998) 275-283
6. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer 39 (1977) 456-466
7. 99mTc in biomedical products. J. Nucl. Med. 12 (1971) 596-600
8. 99mTc in biomedical products. II. The chelation of reduced Tc with DTPA. J. Nucl. Med. 13 (1972) 577-581
9. Edreira M.M., Colombo L.L., Perez J.H., Sajaroff E.O., and Castiglia S.G. In vivo evaluation of three different 99m-Tc labelled radiopharmaceuticals for sentinel lymph node identification. Nucl. Med. Commun. 22 (2001) 499-504
10. Eshima D., Fauconnier Th., Eshima L., and Thornback J.R. Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. Semin. Nucl. Med. 1 (2000) 25-32
11. Gommans G.M.M., Boer R.O., van Dongen A., van der Schors T.G., and de Waard J.W.D. Optimising of Tc-99m-Nanocoll sentinel node localisation in carcinoma of the breast. Eur. J. Nucl. Med. 27 (2000) 744
12. ® sentinel node localisation in carcinoma of the breast by improved labelling. Eur. J. Nucl. Med. 28 (2001) 1450-1455
13. 99Tc ratios on count rates in sentinel node procedures: a randomised study. Eur. J. Nucl. Med. 30 (2003) 1231-1235
14. Haigh P.I., Hansen N.M., Guilliano A.E., Edwards G.K., Ye W., and Glass E.C. Factors affecting sentinel node localisation during preoperative breast lymphoscintigraphy. J. Nucl. Med. 41 (2000) 1682-1688
15. Hodgson N., Zabel P., Mattar A.G., Engel C.J., Girvan D., and Holliday R. A new radiopharmaceutical for sentinel node detection in breast cancer. Ann. Surg. Oncol. 8 (2001) 133-137
16. Imoto S., Murakami K., Ikeda H., Fukukita H., and Moriyama N. Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. Ann. Nucl. Med. 13 (1999) 325-329
17. Kaplan W.D., Davies M.A., and Rose C.H.N. A comparison of two Tc-99m labelled radiopharmaceuticals for lymphoscintigraphy: concise communication. J. Nucl. Med. 20 (1979) 933-937
18. Krag D.N., Weaver D.L., Alex J.C., and Fairbank J.C. Surgical resection and radiolocalisation of the sentinel node in breast cancer using a gammaprobe. Surg. Oncol. 2 (1993) 335-339
19. Krynyckyi B.R., Zhang Z.Y., Kim C.K., Lipszic H., Mosci K., and Machac J. Effect of high specific activity sulphur colloidal preparations on sentinel node count rates. Clin. Nucl. Med. 27 (2001) 92-95
20. -: carrier free?. J. Nucl. Med. 16 (1975) 639-641
21. ®. SPC, October 1999
22. Pijpers R., Borgstein P.J., Meijer S., et al. Transport and retention of colloid tracers in regional lymphoscintigraphy in melanoma: influence on lymphatic mapping and sentinel node biopsy. Melanoma Res. 8 (1998) 413-418
23. Reintgen D. The role of lymphoscintigraphy in lymphatic mapping for melanoma and breast cancer. J. Nucl. Med. 12 (1998) 22n-36n
24. Saha, G.B., 1992. Fundamentals of Nuclear Medicine, third ed., pp. 98-106 (Chapter 6).
25. Schu{combining double acute accent}michen C., Hohloch H., Schiller A., Pohle W., and Hoffman G. Complexing of reduced Tc and tin (II) by chelating phosphate compounds. I. Chemical state of Tc. Nuklearmedizin 18 (1979) 98-104
26. Stalteri M.A., Bansal S., Hider R.C., and Mather S.J. Comparison of the stability of Tc-labelled peptides to challenge with cysteine. Bioconjugate Chem. 10 (1999) 130-136
27. Valdés Olmos R.A., Hoefnagel C.A., Nieweg O.E., Jansen L., Rutgers E.J.T., Borger J., Horenblas S., and Kroon B.B.R. Lymphoscintigraphy in oncology: a rediscovered challenge. Eur. J. Nucl. Med. 226 Suppl (1999) S2-S10
28. Valdés Olmos R.A., Tanis P.J., Hoefnagel C.J., Nieweg O.E., Jansen L., Muller S.H., et al. Improved sentinel node visualisation in breast cancer by optimising the colloidal particle concentration and tracer dosage. Nucl. Med. Commun. 22 (2001) 579-586